Seeking Alpha
 

CTI BioPharma Corp. (CTIC)

- NASDAQ
  • Fri, Mar. 13, 9:25 AM
    • CTI BioPharma Corp. (CTIC -2.6%) Q4 results: Revenues: $17.8M (-45.9%); COGS: $0.3M (+900.0%); R&D Expense: $21.9M (+119.0%); SG&A: $13.1M (+4.8%); Operating Loss: ($39.4M) (-482.5%); Net Loss: ($44.2M) (-533.3%); Loss Per Share: ($0.27) (-437.5%).
    • FY2014 results: Revenues: $60.1M (+73.2%); COGS: $0.9M (+800.0%); R&D Expense: $64.6M (+92.3%); SG&A: $56.2M (+32.9%); Operating Loss: ($86.2M) (-107.7%); Net Loss: ($96M) (-93.5%); Loss Per Share: ($0.65) (-51.2%); Quick Assets: $70.9M (+1.0%).
    • 2015 Guidance: Total revenues: ~ $50M - 55M; non-GAAP operating loss: ~ $75M - 85M.
    | 2 Comments
  • Thu, Mar. 12, 4:05 PM
    • CTI BioPharma (NASDAQ:CTIC): Q4 EPS of -$0.27 misses by $0.09.
    • Revenue of $17.78M (-45.9% Y/Y) beats by $15.3M.
    • Press Release
    | 4 Comments
  • Oct. 29, 2014, 7:00 PM
    • CTI BioPharma Corp (CTIC -5.1%) Q3 results: Revenues: $39.5M (+9775.0%); Operating Expenses: $31.8M (+101.3%); Operating Income: $7.5M (+148.4%); Net Income: $4.6M (+129.9%); EPS: $0.03 (+115.0%); Quick Assets: $29.9M (-58.2%).
    • 2014 Guidance: Non-GAAP Operating Loss: $66M - 71M from $45M - 50M.
    | 2 Comments
  • Oct. 29, 2014, 4:09 PM
    • CTI BioPharma (NASDAQ:CTIC): Q3 EPS of -$0.03 in-line.
    • Revenue of $39.53M (+9782.5% Y/Y) beats by $15.23M.
    • Press Release
    | Comment!
  • Aug. 4, 2014, 4:37 PM
    • CTI BioPharma Corp. (CTIC +2.9%) Q2 results: Total Revenues: $1.3M (+338.9%); Operating Costs: $28.0M (+53.8%); Operating Loss: ($26.7M) (-49.2%); Net Loss: ($27.4M) (-52.2%); Loss Per Share: ($0.19) (-11.8%); Quick Assets: $33.2M (-53.6%).
    • No guidance given.
    | Comment!
  • Aug. 4, 2014, 4:07 PM
    • CTI BioPharma (NASDAQ:CTIC): Q2 EPS of -$0.19
    • Revenue of $1.3M (+282.4% Y/Y)
    • Press Release
    | Comment!
  • Mar. 4, 2014, 4:49 PM
    • Cell Therapeutics (CTIC) Q4 revenue balloons to $32.9M versus $0 a year ago. Almost all of the revenue is due to Baxter's (BAX) upfront payment of $32.4M for the license to develop and commercialize pacritinib.
    • Product revenues for Q4 and FY13 were $.5M and $2.3M, respectively.
    • Net income for the quarter was $10.2M ($.08/share) due to the Baxter payment. Net loss for the year was $49.6M ($.43/share).
    • FY14 guidance projects a loss from operations of $45M - $50M.
    • Consensus estimate for Q1 is a loss of $.23/share on revenues of $1.3M.
    • Consensus estimate for 2014 is a loss of $.48/share on revenues of $23.9M.
    • Mutual fund ownership has increased from 30 to 85 the past 4 quarters.
    | 1 Comment
  • Oct. 30, 2013, 7:23 PM
    • Cell Therapeutics (CTIC): Q3 EPS of -$0.20 misses by $0.03.
    • Revenue of $362K. (PR)
    | Comment!
  • Jul. 31, 2013, 7:12 PM
    • Cell Therapeutics (CTIC): Q2 EPS of -$0.17 in-line.
    • Revenue of $306K beats by $1194M. (PR)
    | Comment!
  • Feb. 28, 2013, 5:47 PM
    Cell Therapeutics (CTIC): Q4 EPS of -$0.20 in-line. (PR)
    | Comment!
  • Aug. 1, 2012, 4:34 AM
    Cell Therapeutics (CTIC): Q2 EPS of -$0.28. As of June 30, the company had ~$14.8M in cash and cash equivalents. European launch of Pixuvri is targeted for Q4. Steven E. Benner named Chief Medical Officer. Targets cut in net operating burn rate to an average of $4.5M/month for the rest of 2012 from $6.5M/month. (PR)
    | Comment!
Visit Seeking Alpha's
CTIC vs. ETF Alternatives
Company Description
CTI BioPharma Corp., is a biopharmaceutical company focused on the acquisition, development and commercialization of less toxic and more effective ways to treat cancer.
Sector: Healthcare
Industry: Biotechnology
Country: United States